INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 202 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is 1.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $735 | +293.0% | 54,751 | +261.1% | 0.07% | +257.9% |
| Q4 2022 | $187 | -99.9% | 15,163 | +208.3% | 0.02% | -68.3% |
| Q1 2020 | $310,000 | +30.8% | 4,918 | +108.5% | 0.06% | +46.3% |
| Q4 2018 | $237,000 | -71.2% | 2,359 | -65.3% | 0.04% | -73.7% |
| Q2 2017 | $824,000 | +99.0% | 6,798 | +85.6% | 0.16% | +60.8% |
| Q1 2017 | $414,000 | – | 3,662 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |